← The record

Milk Powder - Lactose Intolerance Formula

Recommended · restricted OtherAuthority RequiredNot applicable line

Treatment of acute lactose intolerance in infants up to 12 months of age.

1
Submissions
1 resub
2017–17
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Mar 2017
    Recommended · restricted

    vs S-26 LF (milk powder lactose-free formula)

  2. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC recommended the listing of S-26 Original LI as a Authority Required (telephone) benefit for the treatment of acute lactose intolerance, on a cost- ® minimisation basis against S-26 LF at an equivalent DPMQ. ®PSD · Mar 2017
6.2 The PBAC noted the advice of the NPWP that supported the listing of S-26 Original LI on the PBS.PSD · Mar 2017
Clinical claim
5.6 In the pre-PBAC response (p1), the sponsor requested that S-26 Original LI be listed for both acute and proven chronic lactose intolerance to maintain consistency. ® The sponsor stated that the currently-listed S-26 LF includes both indications, as do other milk formulas for lactose intolerance on the PBS, such as Aptamil Gold+ De- Lact®.PSD · Mar 2017

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated as this is a minor submission with equivalent pricing to the comparator product.

Cost-effectiveness accepted

Decision context

PopulationInfants up to 12 months of age with acute lactose intolerance.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2017 Recommended · restricted S-26 LF (milk powder lactose-free formula) Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to acute lactose intolerance treatment; TGA label is a broad infant formula food for special medical purposes.